Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells

Hila Shaim(The University of Texas MD Anderson Cancer Center), Mayra Shanley(The University of Texas MD Anderson Cancer Center), Rafet Başar(The University of Texas MD Anderson Cancer Center), May Daher(The University of Texas MD Anderson Cancer Center), Joy Gumin, Daniel B. Zamler(Center for Genomic Science), Nadima Uprety(The University of Texas MD Anderson Cancer Center), Fang Wang, Yuefan Huang, Konrad Gabrusiewicz, Qi Miao, Jinzhuang Dou, Abdullah Alsuliman(The University of Texas MD Anderson Cancer Center), Lucila Nassif Kerbauy(The University of Texas MD Anderson Cancer Center), Sunil Acharya(The University of Texas MD Anderson Cancer Center), Vakul Mohanty, Mayela Carolina Mendt(The University of Texas MD Anderson Cancer Center), Sufang Li(The University of Texas MD Anderson Cancer Center), JunJun Lu(The University of Texas MD Anderson Cancer Center), Jun Wei, Natalie W. Fowlkes(University of Veterinary Medicine), Elif Gokdemir(The University of Texas MD Anderson Cancer Center), Emily L. Ensley(The University of Texas MD Anderson Cancer Center), Mecit Kaplan(The University of Texas MD Anderson Cancer Center), Cynthia Kassab, Li Li(The University of Texas MD Anderson Cancer Center), Gonca Ozcan(The University of Texas MD Anderson Cancer Center), Pinaki P. Banerjee(The University of Texas MD Anderson Cancer Center), Yifei Shen, April L. Gilbert(The University of Texas MD Anderson Cancer Center), Corry M. Jones(The University of Texas MD Anderson Cancer Center), Mustafa Bdiwi(The University of Texas MD Anderson Cancer Center), Ana Karen Nunez Cortes(The University of Texas MD Anderson Cancer Center), Enli Liu(The University of Texas MD Anderson Cancer Center), Jun Yu, Nobuhiko Imahashi(The University of Texas MD Anderson Cancer Center), Luis Muniz-Feliciano(The University of Texas MD Anderson Cancer Center), Ye Li(The University of Texas MD Anderson Cancer Center), Jian Hu, Giulio Draetta(Center for Genomic Science), David Marín(The University of Texas MD Anderson Cancer Center), Dihua Yu(The University of Texas MD Anderson Cancer Center), Stephan Mielke(University of Würzburg), Matthias Eyrich(Universitätsklinikum Würzburg), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Ken Chen, Frederick F. Lang, Elizabeth J. Shpall(The University of Texas MD Anderson Cancer Center), Amy B. Heimberger, Katayoun Rezvani(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Investigation
June 17, 2021
Cited by 247Open Access
Full Text

Abstract

Glioblastoma multiforme (GBM), the most aggressive brain cancer, recurs because glioblastoma stem cells (GSCs) are resistant to all standard therapies. We showed that GSCs, but not normal astrocytes, are sensitive to lysis by healthy allogeneic natural killer (NK) cells in vitro. Mass cytometry and single-cell RNA sequencing of primary tumor samples revealed that GBM tumor-infiltrating NK cells acquired an altered phenotype associated with impaired lytic function relative to matched peripheral blood NK cells from patients with GBM or healthy donors. We attributed this immune evasion tactic to direct cell-to-cell contact between GSCs and NK cells via αv integrin-mediated TGF-β activation. Treatment of GSC-engrafted mice with allogeneic NK cells in combination with inhibitors of integrin or TGF-β signaling or with TGFBR2 gene-edited allogeneic NK cells prevented GSC-induced NK cell dysfunction and tumor growth. These findings reveal an important mechanism of NK cell immune evasion by GSCs and suggest the αv integrin/TGF-β axis as a potentially useful therapeutic target in GBM.


Related Papers

No related papers found

Powered by citation graph analysis